TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer
Recombinant, soluble TNF‐related apoptosis‐inducing ligand (TRAIL) is currently being developed as a promising natural immune molecule for trial in cancer patients because it selectively induces apoptosis in transformed or stressed cells but not in most normal cells. In cancer patients, phase 1 and...
Gespeichert in:
| Veröffentlicht in: | Immunology and cell biology 2006-02, Vol.84 (1), p.87-98 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 98 |
|---|---|
| container_issue | 1 |
| container_start_page | 87 |
| container_title | Immunology and cell biology |
| container_volume | 84 |
| creator | Cretney, Erika Shanker, Anil Yagita, Hideo Smyth, Mark J Sayers, Thomas J |
| description | Recombinant, soluble TNF‐related apoptosis‐inducing ligand (TRAIL) is currently being developed as a promising natural immune molecule for trial in cancer patients because it selectively induces apoptosis in transformed or stressed cells but not in most normal cells. In cancer patients, phase 1 and 2 clinical trials using agonistic mAbs that engage the human TRAIL receptors DR4 and DR5 have also provided encouraging results. It is now evident that TRAIL suppresses autoimmune disease in various experimental animal models, suggesting that the therapeutic value of recombinant TRAIL and agonistic DR4 and DR5 mAbs might also extend to the suppression of autoimmune disease. This review provides an insight into our current understanding of the role(s) of TRAIL in disease, with a specific focus on cancer and autoimmunity. We also emphasize biological agents and drugs that sensitize tumour cells to TRAIL‐mediated apoptosis and discuss the potential molecular basis for their sensitization. |
| doi_str_mv | 10.1111/j.1440-1711.2005.01413.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70689593</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70689593</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4883-d325fa07f557af6ae5a994a98c82987e5693328bc58ba4d76c210f54fa8937e3</originalsourceid><addsrcrecordid>eNqNkEuP0zAURi0Emill_gJEQmKXYCd-7oCKeUgzw6YSS-vWcYqrxAl-iOm_J6HVILHCmyv5nvvZ9yBUEFyR-Xw8VIRSXBJBSFVjzCpMKGmqpxdo9dx4iVZYElkqTskleh3jAWMsatlcoEvCKWac8RX6vn28LoPtIdm2gGmc0hhdLJ1vs3F-X_RuD37uxAKK9MMGmGxOzhSwtz4VzheQ0-iGIXuXjsWCGvDGhjfoVQd9tFfnukbb66_bzW15_-3mbvP5vjRUyqZsm5p1gEXHmICOg2WgFAUljayVFJZx1TS13Bkmd0BbwU1NcMdoB1I1wjZr9OEUO4XxZ7Yx6cFFY_sevB1z1AJzqdicsUbv_wEPYw5-_pomQnKO61rhmZInyoQxxmA7PQU3QDhqgvViXh_0IlgvgvViXv8xr5_m0bfnB_JusO3fwbPqGfh0An653h7_O1jfPWy-zBecLEu8O0V4SDnY5wxndmfiN8bPnBw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1786602290</pqid></control><display><type>article</type><title>TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer</title><source>MEDLINE</source><source>Wiley Online Library All Journals</source><creator>Cretney, Erika ; Shanker, Anil ; Yagita, Hideo ; Smyth, Mark J ; Sayers, Thomas J</creator><creatorcontrib>Cretney, Erika ; Shanker, Anil ; Yagita, Hideo ; Smyth, Mark J ; Sayers, Thomas J</creatorcontrib><description>Recombinant, soluble TNF‐related apoptosis‐inducing ligand (TRAIL) is currently being developed as a promising natural immune molecule for trial in cancer patients because it selectively induces apoptosis in transformed or stressed cells but not in most normal cells. In cancer patients, phase 1 and 2 clinical trials using agonistic mAbs that engage the human TRAIL receptors DR4 and DR5 have also provided encouraging results. It is now evident that TRAIL suppresses autoimmune disease in various experimental animal models, suggesting that the therapeutic value of recombinant TRAIL and agonistic DR4 and DR5 mAbs might also extend to the suppression of autoimmune disease. This review provides an insight into our current understanding of the role(s) of TRAIL in disease, with a specific focus on cancer and autoimmunity. We also emphasize biological agents and drugs that sensitize tumour cells to TRAIL‐mediated apoptosis and discuss the potential molecular basis for their sensitization.</description><identifier>ISSN: 0818-9641</identifier><identifier>EISSN: 1440-1711</identifier><identifier>DOI: 10.1111/j.1440-1711.2005.01413.x</identifier><identifier>PMID: 16405656</identifier><language>eng</language><publisher>United States: Nature Publishing Group</publisher><subject>Animals ; Antineoplastic Agents - therapeutic use ; Apo2L ; Apoptosis Regulatory Proteins - immunology ; Apoptosis Regulatory Proteins - therapeutic use ; autoimmune disease ; Autoimmune Diseases - drug therapy ; cancer ; Clinical Trials as Topic ; encephalomyelitis ; Humans ; MD5‐1 ; Membrane Glycoproteins - immunology ; Membrane Glycoproteins - therapeutic use ; Models, Biological ; Neoplasms - drug therapy ; Recombinant Proteins - therapeutic use ; TNF-Related Apoptosis-Inducing Ligand ; Tumor Necrosis Factor-alpha - immunology ; Tumor Necrosis Factor-alpha - therapeutic use</subject><ispartof>Immunology and cell biology, 2006-02, Vol.84 (1), p.87-98</ispartof><rights>2006 Australasian Society for Immunology Inc.</rights><rights>Copyright Nature Publishing Group Feb 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4883-d325fa07f557af6ae5a994a98c82987e5693328bc58ba4d76c210f54fa8937e3</citedby><cites>FETCH-LOGICAL-c4883-d325fa07f557af6ae5a994a98c82987e5693328bc58ba4d76c210f54fa8937e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1440-1711.2005.01413.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1440-1711.2005.01413.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16405656$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cretney, Erika</creatorcontrib><creatorcontrib>Shanker, Anil</creatorcontrib><creatorcontrib>Yagita, Hideo</creatorcontrib><creatorcontrib>Smyth, Mark J</creatorcontrib><creatorcontrib>Sayers, Thomas J</creatorcontrib><title>TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer</title><title>Immunology and cell biology</title><addtitle>Immunol Cell Biol</addtitle><description>Recombinant, soluble TNF‐related apoptosis‐inducing ligand (TRAIL) is currently being developed as a promising natural immune molecule for trial in cancer patients because it selectively induces apoptosis in transformed or stressed cells but not in most normal cells. In cancer patients, phase 1 and 2 clinical trials using agonistic mAbs that engage the human TRAIL receptors DR4 and DR5 have also provided encouraging results. It is now evident that TRAIL suppresses autoimmune disease in various experimental animal models, suggesting that the therapeutic value of recombinant TRAIL and agonistic DR4 and DR5 mAbs might also extend to the suppression of autoimmune disease. This review provides an insight into our current understanding of the role(s) of TRAIL in disease, with a specific focus on cancer and autoimmunity. We also emphasize biological agents and drugs that sensitize tumour cells to TRAIL‐mediated apoptosis and discuss the potential molecular basis for their sensitization.</description><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Apo2L</subject><subject>Apoptosis Regulatory Proteins - immunology</subject><subject>Apoptosis Regulatory Proteins - therapeutic use</subject><subject>autoimmune disease</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>cancer</subject><subject>Clinical Trials as Topic</subject><subject>encephalomyelitis</subject><subject>Humans</subject><subject>MD5‐1</subject><subject>Membrane Glycoproteins - immunology</subject><subject>Membrane Glycoproteins - therapeutic use</subject><subject>Models, Biological</subject><subject>Neoplasms - drug therapy</subject><subject>Recombinant Proteins - therapeutic use</subject><subject>TNF-Related Apoptosis-Inducing Ligand</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><subject>Tumor Necrosis Factor-alpha - therapeutic use</subject><issn>0818-9641</issn><issn>1440-1711</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqNkEuP0zAURi0Emill_gJEQmKXYCd-7oCKeUgzw6YSS-vWcYqrxAl-iOm_J6HVILHCmyv5nvvZ9yBUEFyR-Xw8VIRSXBJBSFVjzCpMKGmqpxdo9dx4iVZYElkqTskleh3jAWMsatlcoEvCKWac8RX6vn28LoPtIdm2gGmc0hhdLJ1vs3F-X_RuD37uxAKK9MMGmGxOzhSwtz4VzheQ0-iGIXuXjsWCGvDGhjfoVQd9tFfnukbb66_bzW15_-3mbvP5vjRUyqZsm5p1gEXHmICOg2WgFAUljayVFJZx1TS13Bkmd0BbwU1NcMdoB1I1wjZr9OEUO4XxZ7Yx6cFFY_sevB1z1AJzqdicsUbv_wEPYw5-_pomQnKO61rhmZInyoQxxmA7PQU3QDhqgvViXh_0IlgvgvViXv8xr5_m0bfnB_JusO3fwbPqGfh0An653h7_O1jfPWy-zBecLEu8O0V4SDnY5wxndmfiN8bPnBw</recordid><startdate>200602</startdate><enddate>200602</enddate><creator>Cretney, Erika</creator><creator>Shanker, Anil</creator><creator>Yagita, Hideo</creator><creator>Smyth, Mark J</creator><creator>Sayers, Thomas J</creator><general>Nature Publishing Group</general><general>Blackwell Science Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>200602</creationdate><title>TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer</title><author>Cretney, Erika ; Shanker, Anil ; Yagita, Hideo ; Smyth, Mark J ; Sayers, Thomas J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4883-d325fa07f557af6ae5a994a98c82987e5693328bc58ba4d76c210f54fa8937e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Apo2L</topic><topic>Apoptosis Regulatory Proteins - immunology</topic><topic>Apoptosis Regulatory Proteins - therapeutic use</topic><topic>autoimmune disease</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>cancer</topic><topic>Clinical Trials as Topic</topic><topic>encephalomyelitis</topic><topic>Humans</topic><topic>MD5‐1</topic><topic>Membrane Glycoproteins - immunology</topic><topic>Membrane Glycoproteins - therapeutic use</topic><topic>Models, Biological</topic><topic>Neoplasms - drug therapy</topic><topic>Recombinant Proteins - therapeutic use</topic><topic>TNF-Related Apoptosis-Inducing Ligand</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><topic>Tumor Necrosis Factor-alpha - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cretney, Erika</creatorcontrib><creatorcontrib>Shanker, Anil</creatorcontrib><creatorcontrib>Yagita, Hideo</creatorcontrib><creatorcontrib>Smyth, Mark J</creatorcontrib><creatorcontrib>Sayers, Thomas J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Immunology and cell biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cretney, Erika</au><au>Shanker, Anil</au><au>Yagita, Hideo</au><au>Smyth, Mark J</au><au>Sayers, Thomas J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer</atitle><jtitle>Immunology and cell biology</jtitle><addtitle>Immunol Cell Biol</addtitle><date>2006-02</date><risdate>2006</risdate><volume>84</volume><issue>1</issue><spage>87</spage><epage>98</epage><pages>87-98</pages><issn>0818-9641</issn><eissn>1440-1711</eissn><abstract>Recombinant, soluble TNF‐related apoptosis‐inducing ligand (TRAIL) is currently being developed as a promising natural immune molecule for trial in cancer patients because it selectively induces apoptosis in transformed or stressed cells but not in most normal cells. In cancer patients, phase 1 and 2 clinical trials using agonistic mAbs that engage the human TRAIL receptors DR4 and DR5 have also provided encouraging results. It is now evident that TRAIL suppresses autoimmune disease in various experimental animal models, suggesting that the therapeutic value of recombinant TRAIL and agonistic DR4 and DR5 mAbs might also extend to the suppression of autoimmune disease. This review provides an insight into our current understanding of the role(s) of TRAIL in disease, with a specific focus on cancer and autoimmunity. We also emphasize biological agents and drugs that sensitize tumour cells to TRAIL‐mediated apoptosis and discuss the potential molecular basis for their sensitization.</abstract><cop>United States</cop><pub>Nature Publishing Group</pub><pmid>16405656</pmid><doi>10.1111/j.1440-1711.2005.01413.x</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0818-9641 |
| ispartof | Immunology and cell biology, 2006-02, Vol.84 (1), p.87-98 |
| issn | 0818-9641 1440-1711 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70689593 |
| source | MEDLINE; Wiley Online Library All Journals |
| subjects | Animals Antineoplastic Agents - therapeutic use Apo2L Apoptosis Regulatory Proteins - immunology Apoptosis Regulatory Proteins - therapeutic use autoimmune disease Autoimmune Diseases - drug therapy cancer Clinical Trials as Topic encephalomyelitis Humans MD5‐1 Membrane Glycoproteins - immunology Membrane Glycoproteins - therapeutic use Models, Biological Neoplasms - drug therapy Recombinant Proteins - therapeutic use TNF-Related Apoptosis-Inducing Ligand Tumor Necrosis Factor-alpha - immunology Tumor Necrosis Factor-alpha - therapeutic use |
| title | TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T03%3A18%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TNF-related%20apoptosis-inducing%20ligand%20as%20a%20therapeutic%20agent%20in%20autoimmunity%20and%20cancer&rft.jtitle=Immunology%20and%20cell%20biology&rft.au=Cretney,%20Erika&rft.date=2006-02&rft.volume=84&rft.issue=1&rft.spage=87&rft.epage=98&rft.pages=87-98&rft.issn=0818-9641&rft.eissn=1440-1711&rft_id=info:doi/10.1111/j.1440-1711.2005.01413.x&rft_dat=%3Cproquest_cross%3E70689593%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1786602290&rft_id=info:pmid/16405656&rfr_iscdi=true |